| Value | ₹680.0 Cr |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹734.95
- Market cap
- ₹11,568 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 31.8×Sector 43.0×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Other fund raise announcements
All →United Van Der Horst Fund Raise of ₹2 Cr
United Van Der Horst's board approved a preferential issue of 62.50 lakh equity shares at Rs.32 each, raising about Rs.2.00 Crore. The record date is set for 30 November 2026.
- Value
- ₹2.00 Cr
SML Mahindra Fund Raise of ₹1,450 Cr
SML Mahindra announced a board-approved rights issue of fully paid-up equity shares at Rs. 10 face value for up to Rs. 1450 Crore. Terms, record date and regulatory approvals remain pending.
- Value
- ₹1,450 Cr
Richa Info Systems Fund Raise of ₹50 Cr
Richa Info Systems board approved raising funds up to ₹50 crore, with mode, terms and instruments yet to be finalised. Investors should await the detailed fundraising terms.
- Value
- ₹50.00 Cr
S J Logistics (India) Fund Raise of ₹92.58 Cr
SJ Logistics' board approved a preferential issue of equity shares and warrants at Rs.326 each, raising about Rs.92.58 Crore. Shareholder approval is sought at an EGM on 7 December 2026.
- Value
- ₹92.58 Cr
Flywings Simulator Training Centre Fund Raise of ₹73.2 Cr
Flywings approved preferential issue of up to 29,87,760 warrants at Rs 245, aggregating Rs 73.20 crore. Shareholder approval is sought at an EGM on November 27, 2026.
- Value
- ₹73.20 Cr
Upsurge Investment & Finance Fund Raise of ₹20 Cr
Upsurge Investment & Finance approved unaudited Q2 FY27 results, appointed Manish Kabra as CFO, and approved raising up to Rs.20 Crore. The raise needs shareholder and regulatory approvals before proceeding.
- Value
- ₹20.00 Cr